Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

NCT01955720 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemorrhage

Interventions

DRUG: BI 655075
DRUG: BI 655075
DRUG: Placebo
DRUG: BI 655075
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: BI 655075

Sponsor

Boehringer Ingelheim